<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-126511</identifier>
<setSpec>1130-5665</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">A prospective protocol of oral anticoagulation in patients with chronic nonvalvular atrial fibrillation: effectiveness and safety in daily clinical practice</dc:title>
<dc:description xml:lang="en">Introduction: Our objective is to evaluate if a prospective protocol of oral anticoagulation in patients with nonvalvular atrial fibrillation, based in ClinicalPractice Guidelines of the Spanish Society of Cardiology, is effective and safe in daily clinical practice. Patients and method: From February 1st, 2000 until February 1st, 2002, we enrolled all patients with chronic nonvalvular atrial fibrillation visited in  two outpatient cardiology clinics and we prospectively followed them, analysingmajor events (death, systemic embolism and severe haemorrhage) by group of treatment. Results: 624 patients fulfilled inclusion criteria, and 425 were anticoagulated (68%). Anticoagulated patients showed a higher frequency of hypertension (75% versus 53%, p &lt; 0.001), diabetes (28% versus 15%, p &lt; 0.001), previous embolism (19% versus 5%, p &lt; 0.001) and ischaemic heart disease (11% versus 4%, p = 0.003), a greater number of cardioembolic risk factors (2.2±1.1 versus 1.6±1.2, p &lt; 0.001) and a lower frequency of lone atrial fibrillation (15% versus 40%, p &lt; 0.001) than non-anticoagulated patients. These latter ones were antiagregated in 93% of cases (92% with aspirin). After a mean follow-up of 22 ± 14 months (95% of patients with follow-up completed) embolic event rate for year (0.82% versus 7.17%, p &lt; 0.001) and yearly  mortality (1.98% versus 5.18%, p = 0.007) were lower in anticoagulated patients than in the rest of the series, without a significant increase in severe haemorrhage rate for year (1.37% versus 1.36%, p = 0.82). Conclusions: Oral anticoagulation in nonvalvular atrial fibrillation is effective and safe in daily clinical practice (AU)</dc:description>
<dc:creator>Franco Zapata, M</dc:creator>
<dc:creator>Vallés Belsué, F</dc:creator>
<dc:creator>Romo Peñas, E</dc:creator>
<dc:creator>Mesa Rubio, D</dc:creator>
<dc:creator>Ruiz Ortiz, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: Nuestro trabajo pretende valorar si un protocolo prospectivo de anticoagulación en la fibrilación auricular no valvular, basado en las Guías de Práctica Clínica de la Sociedad Española de Cardiología, es efectivo y seguro en la práctica clínica diaria. Pacientes y métodos: Desde el 1.2.2000 hasta el 1.2.2002 se han incluido en el protocolo todos los pacientes con fibrilación auricular no valvular crónica revisados en dos consultas de cardiología y se han seguido prospectivamente, analizando los eventos mayores (muerte, embolismos sistémicos o hemorragia severa) por grupo de tratamiento. Resultados: De 624 pacientes incluidos, fueron anticoagulados 425 (68%). Los pacientes anticoagulados presentaron una mayor frecuencia de hipertensión (75% versus 53%, p &lt; 0.001), diabetes (28% versus 15%, p &lt;  0.001), embolismo previo (19% versus 5%, p &lt; 0.001) y cardiopatía isquémica (11% versus 4%, p = 0.003), un mayor número de factores de riesgo cardioembólicos (2.2 ± 1.1 versus 1.6 ± 1.2, p &lt; 0.001) y una menor frecuencia de fibrilación auricular aislada (15% versus 40%, p &lt; 0.001) que los pacientes no anticoagulados. Éstos últimos fueron antiagregados en el 93% de los casos (92% con aspirina). Tras un seguimiento de 22 ± 14 meses (95% de pacientes seguidos) la tasa anual de eventos embólicos (0.82% versus 7.17%, p &lt; 0.001) y la de mortalidad (1.98% versus 5.18%, p = 0.007) fueron menores en los pacientes nticoagulados que en el resto, sin un aumento significativo en la tasa anual de hemorragias severas (1.37% versus 1.36%, p = 0.82). Conclusión: El tratamiento anticoagulante en la fibrilación auricular no  valvular es efectivo y seguro en la práctica clínica diaria (AU)</dc:description>
<dc:source>MAPFRE med;15(4): 233-243, oct.-dic. 2004. tab, graf</dc:source>
<dc:identifier>ibc-126511</dc:identifier>
<dc:title xml:lang="es">Un protocolo prospectivo de anticoagulación oral en los pacientes con fibrilación auricular crónica no valvular: efectividad y seguridad en la práctica clínica diaria</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d1287^s22057</dc:subject>
<dc:subject>^d7152^s22080</dc:subject>
<dc:subject>^d3942^s22080</dc:subject>
<dc:subject>^d932^s22073</dc:subject>
<dc:subject>^d16735</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d34247^s22054</dc:subject>
<dc:type>article</dc:type>
<dc:date>200412</dc:date>
</metadata>
</record>
</ibecs-document>
